A study, at the Paracelsus University Salzburg in Austria, to be published in the March issue of the Journal of the American Society of Nephrology, enrolled 286 patients with diabetic nephropathy, albuminuria with a urinary albumin excretion rate of 0.2 to 5.6 mg/min and blood pressure below 180/110 mm Hg. The patients were randomly assigned to avosentan or placebo along with standard ACE inhibitor or angiotensin receptor blocker therapy. After 12 weeks of treatment the avosentan group had significant reduction of albuminuria, even with lower doses of avosentan, while the placebo group had not.